For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and Attruby represents a true advancement . These groundbreaking therapies stabilize the transthyretin protein, slowing its damaging build-up and alleviating the impact of